Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on November 14th, 2023%
A company formed earlier this year is developing precision treatments for bacteria resistant to conventional antibiotics, and raising £4.3 million ($US 5.4 million) in seed funds. . . . → Read More: Start-Up Developing Precision Antibiotics for Resistant Bacteria
By Alan, on November 8th, 2023%
A new-business accelerator program, begun earlier this year to advance and commercialize biomedical research discoveries from academic labs, is receiving a $100 million founding grant. . . . → Read More: Life Science Incubator Gains $100M in Start-Up Funds
By Alan, on October 19th, 2023%
An historically Black medical college and pharmaceutical industry group began a program to increase the numbers of people of African descent in genomic databases. . . . → Read More: Coalition to Boost African Ancestry Genomic Data
By Alan, on October 18th, 2023%
The U.S. government’s health preparedness agency awarded a contract with a university lab to explore organ models on chips to document effects of radiation sickness. . . . → Read More: Organ Chip Devices to Model for Radiation Sickness
By Alan, on October 17th, 2023%
A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler. . . . → Read More: Start-Up Adapts Crispr for Molecular Detection, Raises $40M
By Alan, on October 12th, 2023%
An organization funding research on extending the human life span by preventing age-related diseases is founding its first biotechnology company. . . . → Read More: Longevity Science Group Spins-Off Biotech Start-Up
By Alan, on October 11th, 2023%
A developer of therapies addressing the body’s microbe communities is selling off key assets to another biotechnology company, after problems developed with its lead program. . . . → Read More: Collapsed Microbiome Biotech Sells Off Assets
By Alan, on October 9th, 2023%
A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round. . . . → Read More: Neuro Disease Biotech Gains $61M in Early Funds
By Alan, on October 5th, 2023%
Research with lab mice shows an experimental vaccine stimulates the body’s basic immune system to protect against a range of pathogens associated with hospital infections. . . . → Read More: Vaccine Shown to Protect Against Multiple Hospital Pathogens
By Alan, on October 4th, 2023%
A company offering a biomanufacturing process it says is more efficient and scalable than conventional bio-production methods is raising $9.5 million in its first venture round. . . . → Read More: Biomanufacturing Company Gains $9.5M in Early Funds
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|